Core Viewpoint - Bank of America Securities reports that CanSino Biologics (06185) achieved a 31% year-on-year revenue growth in the first half of the year, with a narrowing net loss [1] Revenue and Profitability - Revenue from meningococcal vaccines increased by 38.4% year-on-year, driven by sales growth of MCV4Menhycia [1] - The gross margin for vaccine products improved to 79.3%, up 12 percentage points year-on-year, benefiting from higher profit vaccine sales and increased capacity utilization [1] Earnings Forecast and Rating - Bank of America Securities raised the earnings per share forecast for CanSino by 7%-11% for the years 2028 to 2034, considering the company's leading R&D capabilities across various technological routes and strong overseas expansion potential [1] - The rating for CanSino is reiterated as "Buy," with the target price increased from HKD 43 to HKD 56 [1]